Eli Lilly effects most sensible estimates on Mounjaro energy however slashes full-year benefit outlook
Eli Lilly reported third-quarter income and changed profits that crowned expectancies, lifted by way of $1.4 billion in gross sales from its blockbuster diabetes drug Mounjaro. However the corporate slashed its full-year benefit